Superior Planning, LLC’s Acadia Pharmaceuticals ACAD Stock Holding History

Superior Planning, LLC’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$20	Buy	+1	New	+$27	﹤0.01%	2129

Other funds holding ACAD

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Panagora Asset Management Boston, Massachusetts $33.2B AUM 43.67% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Superior Planning, LLC's ACAD Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Acadia Pharmaceuticals (ACAD) in Q3 2026: 1 share worth $20. The stake represents ﹤0.01% of the portfolio and ranks #2129 among its holdings.

209 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

Superior Planning, LLC held 1 share of Acadia Pharmaceuticals worth $20 as of Q3 2026.
Acadia Pharmaceuticals was a new Superior Planning, LLC position in Q3 2026.
Acadia Pharmaceuticals made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #2129 holding.
209 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.